NICOX SA (ALCOX.PA) Stock Price, Forecast & Analysis
EPA:ALCOX • FR0013018124
ALCOX.PA Key Statistics, Chart & Performance
The current stock price of ALCOX.PA is 0.387 EUR. In the past month the price increased by 11.53%. In the past year, price increased by 25.85%.
ALCOX.PA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ALCOX.PA. When comparing the yearly performance of all stocks, ALCOX.PA is one of the better performing stocks in the market, outperforming 84.52% of all stocks.
ALCOX.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ALCOX.PA. ALCOX.PA may be in some trouble as it scores bad on both profitability and health.
ALCOX.PA Financial Highlights
Over the last trailing twelve months ALCOX.PA reported a non-GAAP Earnings per Share(EPS) of -0.36. The EPS increased by 23.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -179.67% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALCOX.PA Forecast & Estimates
9 analysts have analysed ALCOX.PA and the average price target is 1.53 EUR. This implies a price increase of 295.35% is expected in the next year compared to the current price of 0.387.
For the next year, analysts expect an EPS growth of 96% and a revenue growth 230% for ALCOX.PA
ALCOX.PA Ownership
ALCOX.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 28.02 | 43.529B | ||
| ARGX | ARGENX SE | 28.07 | 43.504B | ||
| 22UA | BIONTECH SE-ADR | N/A | 21.617B | ||
| ABVX | ABIVAX SA | N/A | 8.158B | ||
| 2X1 | ABIVAX SA | N/A | 7.695B | ||
| GXE | GALAPAGOS NV | N/A | 1.868B | ||
| GLPG | GALAPAGOS NV | N/A | 1.866B | ||
| 6IV | INVENTIVA SA | N/A | 1.034B | ||
| IVA | INVENTIVA SA | N/A | 1.008B | ||
| NANO | NANOBIOTIX | N/A | 994.371M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ALCOX.PA
Company Profile
Nicox SA is an ophthalmology company. The company is headquartered in Biot, Paca and currently employs 11 full-time employees. The company is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The firm has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). The company has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.
Company Info
NICOX SA
Sundesk Sophia Antipolis, Batiment C, Emerald Square, rue Evariste Galois
BIOT PACA FR
Employees: 28
Phone: 33497245300
NICOX SA / ALCOX.PA FAQ
What does NICOX SA do?
Nicox SA is an ophthalmology company. The company is headquartered in Biot, Paca and currently employs 11 full-time employees. The company is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The firm has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). The company has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.
What is the stock price of NICOX SA today?
The current stock price of ALCOX.PA is 0.387 EUR. The price increased by 1.84% in the last trading session.
Does NICOX SA pay dividends?
ALCOX.PA does not pay a dividend.
How is the ChartMill rating for NICOX SA?
ALCOX.PA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is ALCOX.PA stock listed?
ALCOX.PA stock is listed on the Euronext Paris exchange.
What do analysts say about NICOX SA (ALCOX.PA) stock?
9 analysts have analysed ALCOX.PA and the average price target is 1.53 EUR. This implies a price increase of 295.35% is expected in the next year compared to the current price of 0.387.
What is the ownership structure of NICOX SA (ALCOX.PA)?
You can find the ownership structure of NICOX SA (ALCOX.PA) on the Ownership tab.